Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
Lancet Gastroenterology & Hepatology 2026; 11:12–21 Epub ahead of print Doi: 10.1016/S2468-1253(25)00233-X.
Vedolizumab achieved higher rates of sustained clinical and endoscopic remission at weeks 26 and 52 in patients with early, biologic-naive Crohn’s disease versus those with longstanding, biologic-experienced disease. Serious adverse events occurred less frequently in the early disease compared with the late disease cohort, supporting the benefit of earlier biologic intervention.
